ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Phico Therapeutics awarded Innovate UK funding for £1.4 million ($1.87M) antibacterial therapy project.
UK China Enterprise joins Puhua Capital in backing Oxsight – an Oxford spin-out set to benefit people suffering from eyesight impairment with its intelligent smart glasses technology.
ET Capital is appointed manager of UK China Enterprise a fund exploiting the potential of UK innovation and technology driven business to scale-up in China.
ADC Therapeutics raises $200 Million in private placing to fund registrational trials of its lead anti-cancer drugs.